Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload
dc.contributor.author | Zhou, Lan | en_US |
dc.contributor.author | Giacherio, Donald A. | en_US |
dc.contributor.author | Cooling, Laura | en_US |
dc.contributor.author | Davenport, Robertson D. | en_US |
dc.date.accessioned | 2010-06-01T22:43:41Z | |
dc.date.available | 2010-06-01T22:43:41Z | |
dc.date.issued | 2005-07 | en_US |
dc.identifier.citation | Zhou, Lan; Giacherio, Donald; Cooling, Laura; Davenport, Robertson D. (2005). "Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload." Transfusion 45(7): 1056-1063. <http://hdl.handle.net/2027.42/75697> | en_US |
dc.identifier.issn | 0041-1132 | en_US |
dc.identifier.issn | 1537-2995 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/75697 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15987348&dopt=citation | en_US |
dc.description.abstract | Transfusion-associated circulatory overload (TACO) occurs when the transfusion rate or volume exceeds the capacity of a compromised cardiovascular system. Characteristic symptoms and signs associated with TACO are neither sensitive nor specific. B-natriuretic peptide (BNP) is a 32-amino-acid polypeptide secreted from the cardiac ventricles in response to ventricular volume expansion and pressure overload. This study was performed to explore the usage of BNP in the differential diagnosis of TACO. STUDY DESIGN AND METHODS: Pre- and posttransfusion BNP levels were determined in 21 patients with suspected TACO and 19 control patients. The BNP was considered significant if the posttransfusion-to-pretransfusion ratio was at least 1.5 and the posttransfusion BNP level was at least 100 pg per mL. RESULTS: The BNP test has a sensitivity and specificity of 81 and 89 percent, respectively, in diagnosis of TACO. It has a positive predictive value of 89 percent, a negative predictive value of 81 percent, and an accuracy of 87 percent. In logistic regression analysis, BNP was found to have significant predictive power independent of other clinical variables in models predicting which patients had TACO. CONCLUSIONS: Our study suggests that in patients who present symptoms suggestive of TACO, BNP can be a useful adjunct marker in confirming volume overload as the cause of acute dyspnea and symptoms related to cardiovascular compromise. | en_US |
dc.format.extent | 199121 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | 2005 American Association of Blood Banks | en_US |
dc.title | Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | From The University of Michigan Medical School, Ann Arbor, Michigan. | en_US |
dc.identifier.pmid | 15987348 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/75697/1/j.1537-2995.2005.04326.x.pdf | |
dc.identifier.doi | 10.1111/j.1537-2995.2005.04326.x | en_US |
dc.identifier.source | Transfusion | en_US |
dc.identifier.citedreference | Audet AM, Popovsky MA, Andrzejewski C. Transfusion-associated circulatory overload in orthopedic surgery patients: a multi-institutional study. Immunohematology 1996; 12: 87 - 9. | en_US |
dc.identifier.citedreference | Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30: 583 - 90. | en_US |
dc.identifier.citedreference | Popovsky MA. Transfusion-related acute lung injury (TRALI). In: Popovsky MS, editor. Transfusion reactions. 2nd ed. Bethesda: American Association of Blood Banks; 2001. p. 155 - 70. | en_US |
dc.identifier.citedreference | Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 1995; 96: 1280 - 7. | en_US |
dc.identifier.citedreference | Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464 - 9. | en_US |
dc.identifier.citedreference | Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825 - 32. | en_US |
dc.identifier.citedreference | Stein BC, Levin R. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998; 135: 914 - 23. | en_US |
dc.identifier.citedreference | Holmes SJ, Espiner BA, Richards AM, et al. Renal, endocrine and haemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91 - 6. | en_US |
dc.identifier.citedreference | Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274 - 9. | en_US |
dc.identifier.citedreference | Wei CM, Heublein DM, Perrella MA, et al. Natriuretic peptide system in human heart failure. Circulation 1993; 88: 1004 - 9. | en_US |
dc.identifier.citedreference | Yamamoto K, Butnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988 - 94. | en_US |
dc.identifier.citedreference | Ogawa T, Linz W, Stevenson M. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 1996; 93: 2059 - 67. | en_US |
dc.identifier.citedreference | Hasegawa K, Fujiwara H, Doyama K. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993; 88: 372 - 80. | en_US |
dc.identifier.citedreference | Davies M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994; 343: 440 - 4. | en_US |
dc.identifier.citedreference | Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379 - 85. | en_US |
dc.identifier.citedreference | McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: an analysis from the Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416 - 22. | en_US |
dc.identifier.citedreference | Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161 - 7. | en_US |
dc.identifier.citedreference | De Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone [review]. Chest 2004; 125: 652 - 68. | en_US |
dc.identifier.citedreference | Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2005; 44 :1774 - 89. | en_US |
dc.identifier.citedreference | Cooling L. Transfusion-related acute lung injury. JAMA 2002; 288: 315 - 6. | en_US |
dc.identifier.citedreference | McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians [review]. Rev Cardiovasc Med 2003; 4: 72 - 80. | en_US |
dc.identifier.citedreference | Gobinet-Georges A, Valli N, Helene F, et al. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med 2000; 38: 519 - 23. | en_US |
dc.identifier.citedreference | Danielson CF, Rothenberger S, Wilson S, et al. Suspected transfusion reactions associated with an increase in respiratory rate. Transfusion 2003; 43: 22S. | en_US |
dc.identifier.citedreference | Burgher AH, Aslan D, Laudi N, et al. Use of brain natriuretic peptide to evaluate transfusion-related acute lung injury. Transfusion 2004; 44: 1533 - 4. | en_US |
dc.identifier.citedreference | Cheung BM, Kumana CR. Natriuretic peptides: relevance in cardiac disease. JAMA 1998; 280: 1983 - 4. | en_US |
dc.identifier.citedreference | de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316 - 22. | en_US |
dc.identifier.citedreference | Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47: 287 - 96. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.